Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Open Angle Glaucoma: Treatment

Open Angle Glaucoma: Treatment

In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...

Angle Closure Glaucoma: Treatment

Angle Closure Glaucoma: Treatment

Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...

Direct-Acting Cholinergic Agonists: Therapeutic Uses

Direct-Acting Cholinergic Agonists: Therapeutic Uses

Direct-acting cholinergic agonists have many therapeutic uses in various medical fields. Choline esters, including acetylcholine, have limited clinical utility due to their non-selectivity and short duration of action. Still, acetylcholine and carbachol are applied topically during ophthalmologic surgery to induce miosis. Pilocarpine, a muscarinic and ganglionic stimulator, effectively treats open-angle glaucoma and alleviates xerostomia and dry mouth caused by radiotherapy or Sjögren syndrome.

Drugs Acting on Autonomic Ganglia: Blockers

Drugs Acting on Autonomic Ganglia: Blockers

Ganglionic blockers inhibit autonomic activity by blocking nicotinic receptors in the autonomic ganglia, suppressing impulse transmission. These blockers lack selectivity between sympathetic and parasympathetic ganglia and are ineffective as neuromuscular junction antagonists. They can be categorized into two groups:

Management of Insomnia

Management of Insomnia

The sleep cycle, an integral part of human health, consists of several stages with distinct characteristics and functions. It begins with a transition from wakefulness to sleep, known as the light sleep phase, followed by the restorative deep sleep phase, essential for physical recovery and growth. The cycle concludes with the Rapid Eye Movement (REM) phase, characterized by high brain activity and vivid dreaming. Insomnia, a prevalent sleep disorder, involves difficulty falling asleep, staying...

Cholinergic Antagonists: Pharmacokinetics

Cholinergic Antagonists: Pharmacokinetics

Cholinergic antagonists—such as antimuscarinics—are available in oral, topical, ocular, parenteral, and inhalational formulations. Most antimuscarinics are oral formulations, while scopolamine is available as a topical patch, and ipratropium and tiotropium are available as inhalation aerosols or powders. Atropine, tropicamide, and cyclopentolate are topically instilled in the eye. Most antimuscarinics are lipid-soluble and readily absorbed from the gastrointestinal tract and the conjunctiva.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Chinook winds and migraine attack onset in children and adolescents: A prospective longitudinal clinical cohort study.

Headache·2025

Same author

The Healthcare Cost of Migraine: A Retrospective Cohort Study from Alberta, Canada.

The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques·2025

Same author

To treat or not to treat? Medication underuse headache, a novel reframing.

Cephalalgia : an international journal of headache·2024

Same author

The 5-HT<sub>1B</sub> and 5-HT<sub>1D</sub> agonists in acute migraine therapy: Ergotamine, dihydroergotamine, and the triptans.

Handbook of clinical neurology·2024

Same author

OnabotulinumtoxinA Improves Quality of Life in Chronic Migraine: The PREDICT Study - CORRIGENDUM.

The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques·2023

Same author

CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne·2023

Search research articles

Related Experiment Video

Updated: May 10, 2026

3D-Neuronavigation In Vivo Through a Patient's Brain During a Spontaneous Migraine Headache

3D-Neuronavigation In Vivo Through a Patient's Brain During a Spontaneous Migraine Headache

Published on: June 2, 2014

Cluster headache: conventional pharmacological management.

Werner J Becker¹

¹Department of Clinical Neurosciences, University of Calgary and Alberta Health Services, Calgary, AB, Canada.

|June 19, 2013

Summary

This summary is machine-generated.

Cluster headache management involves acute treatments like oxygen and triptans, transitional therapies, and prophylactic options such as verapamil. Effective treatment requires addressing the intense pain and therapeutic challenges of cluster headache attacks.

Keywords:

cluster headache prophylactic medication transitional medications

More Related Videos

An Automated Squint Method for Time-syncing Behavior and Brain Dynamics in Mouse Pain Studies

An Automated Squint Method for Time-syncing Behavior and Brain Dynamics in Mouse Pain Studies

Published on: November 1, 2024

Dural Stimulation and Periorbital von Frey Testing in Mice As a Preclinical Model of Headache

Dural Stimulation and Periorbital von Frey Testing in Mice As a Preclinical Model of Headache

Published on: July 29, 2021

Related Experiment Videos

Last Updated: May 10, 2026

3D-Neuronavigation In Vivo Through a Patient's Brain During a Spontaneous Migraine Headache

3D-Neuronavigation In Vivo Through a Patient's Brain During a Spontaneous Migraine Headache

Published on: June 2, 2014

An Automated Squint Method for Time-syncing Behavior and Brain Dynamics in Mouse Pain Studies

An Automated Squint Method for Time-syncing Behavior and Brain Dynamics in Mouse Pain Studies

Published on: November 1, 2024

Dural Stimulation and Periorbital von Frey Testing in Mice As a Preclinical Model of Headache

Dural Stimulation and Periorbital von Frey Testing in Mice As a Preclinical Model of Headache

Published on: July 29, 2021

Area of Science:

Neurology
Pain Medicine
Pharmacology

Background:

Cluster headache is characterized by severe, rapidly escalating pain and frequent attacks.
These features present significant therapeutic challenges for clinicians.
Understanding effective treatment strategies is crucial for patient care.

Purpose of the Study:

To review current pharmacological treatment options for acute cluster headache attacks.
To discuss transitional therapy for high-frequency episodic cluster headache.
To outline prophylactic therapy options for both episodic and chronic cluster headache.

Main Methods:

Review of established and emerging pharmacological treatments.
Discussion of therapeutic strategies based on attack frequency and headache type.
Emphasis on evidence-based recommendations for cluster headache management.

Main Results:

Effective acute treatments include subcutaneous sumatriptan, 100% oxygen, and intranasal zolmitriptan.
Transitional therapies involve corticosteroids, dihydroergotamine, and nerve blocks for frequent attacks.
Verapamil is the primary prophylactic choice, requiring cardiac monitoring (EKGs), with lithium as another option.

Conclusions:

A multi-faceted approach is necessary for cluster headache management, combining acute, transitional, and prophylactic therapies.
Verapamil is a key prophylactic agent, necessitating careful monitoring due to potential cardiac side effects.
Further research is needed to establish evidence for other therapeutic agents.